Pharmaceutical Business Review

DECEMBER 20, 2024

These funds are expected to extend Assembly Bio’s cash runway to mid-2026 and will support the progression of its clinical pipeline, including the anticipated interim Phase Ib proof-of-concept data for ABI-5366 in the first half of the next year.

Compounding 52

Compounding 52

Pharmaceutical Technology

JULY 26, 2022

The three major markets (3MM: the US, Germany and the UK) will increase in market size from $128.35m last year to $188.35m in 2031, at a compound annual growth rate (CAGR) of 3.9%. This sales growth will be in line with a steadily increasing disease prevalence and the entrance of novel agents into the market.

Labelling 122

Labelling Compounding 122

Pharmaceutical Business Review

MARCH 7, 2024

Additionally, Sionna is progressing with the development of compounds targeting complementary mechanisms. This capital raise provides financial flexibility positioning us to execute our clinical development plan with funding through 2026 and multiple value-creating clinical readouts.”

Drug Development 59

Drug Development Compounding 59

LifeProNow

MARCH 27, 2023

The estimated compounded annual growth rate is more than 26 percent reaching $1.36 billion in sales by 2026. Bayer has exclusive worldwide marketing rights for this product including the U.S. The medical imaging AI market is the fastest growing segment within the global radiology industry.

Bioethics 130

Bioethics Compounding Diabetes 130

pharmaphorum

JUNE 2, 2022

By 2026, the report predicts that each of the top 10 selling orphan drugs will earn between $3 billion and $13 billion. The report estimates that the orphan drug market will grow twice as fast as the non-orphan market, with a 2021 to 2026 compound annual growth rate of 12%.

Compounding 52

Compounding Pharmaceutical Companies Pharmaceutical Companies Drug Pricing 52

pharmaphorum

JANUARY 10, 2023

Approximately 30% of global data volume is generated by the healthcare industry and it will continue to expand with a compound annual growth rate predicted to reach 36% by 2025, according to research by RBC Capital Markets. billion by 2026, according to research by the Business Research Company. billion in 2021 to $9.23

Compounding 98

Compounding Communication Pharmaceutical Companies Pharmaceutical Companies 98

pharmaphorum

JANUARY 18, 2023

AI-based medical imaging was a market worth more than $400 million in 2021, according to figures cited by Bayer, and is expected to have a compound annual growth rate (CAGR) of more than 26% between 2020 to 2026, driving its value to around $1.36

Compounding 59

Compounding 59

FDA Law Blog: Biosimilars

DECEMBER 3, 2023

On November 17th, CMS issued its final guidance on the Discount Program in which it responded to public comments and provided updated guidance for the Discount Program for 2025 and 2026. The Discount Program is similar to the CGDP with respect to several requirements and operational processes, and CMS will implement it in a similar manner.

Labelling 105

Labelling Drug Pricing Compounding Payment Processing 105

PharmaShots

FEBRUARY 22, 2023

In the US, Trulicity is protected by a compound patent (2027) and by biologics data protection (2026). Hence, it needs to protect its patent as Trulicity patents are very vital to the company’s business as a whole.

Diabetes 64

Diabetes Compounding Dosage Communication 64

pharmaphorum

APRIL 24, 2022

In a statement, the drugmaker said “we stand by the safety of aducanumab, and we look forward to upcoming data readouts to continue to provide important information on the science of this new class of compound.”

Compounding 52

Compounding 52

Viseven

SEPTEMBER 18, 2024

By the end of 2026, the company will be able to analyze two million genomes. It is no surprise that the global market is growing at a compound annual rate of 20%. This innovative approach has brought more than 40 successful drug discovery projects to AstraZeneca.

Communication 52

Communication Vaccines Pharmaceutical Companies Pharmaceutical Companies 52

Pharmaceutical Technology

JANUARY 10, 2023

billion in 2029, with drug sales almost doubling at a compound annual growth rate (CAGR) of 11.5%. GlobalData expects that the T2D market will see significant growth from 2019–29, with the 9MM having a total of $45.9 billion in sales in 2019, increasing to $136.2

Biosimilars 52

Biosimilars Labelling Diabetes Compounding 52

European Pharmaceutical Review

AUGUST 19, 2022

billion by 2026. percent compound annual growth rate (CAGR) of the market include the increasing commercialisation of generics and emerging technologies and small biotechs with limited or no production capabilities driving development in the biopharmaceutical sector. percent between 2021 and 2026 (the forecast period).

Packaging 98

Packaging Compounding 98

Express Pharma

NOVEMBER 2, 2023

Against this backdrop, the CD drug sales across the eight-major markets (8MM*) are set to increase at a compound annual growth rate (CAGR) of 4.7 The anticipated launches in the US and Europe of Janssen’s Tremfya (guselkumab) and Lilly’s mirikizumab, in Q4 2025 and Q3 2026, respectively, are expected to shape the market.

Biosimilars 100

Biosimilars Compounding 100

pharmaphorum

MARCH 14, 2022

Novel Compounds and Treatments for Pain: Opioids and the Alternatives. Million by 2026, growing at a CAGR of 4.40 % from 2019 to 2026. Sponsored by: CHDR. Conference Chairman: Richard Malamut, Chief Medical Officer, Collegium Pharmaceutical, Inc. The global Postoperative Pain Therapeutics Market was valued at USD 11.26

Compounding 52

Compounding Drug Development 52

RX Note

FEBRUARY 4, 2024

Introduction In parallel with industrialization, the focus of pharmacists' practice has evolved from compounding and dispensing medications to the provision of professional services for patients. As experts in medicines, pharmacists can review complex medicine regimens and identify causes of problems and resolve them.

Community Pharmacies 52

Community Pharmacies Medical Records Compounding Diabetes 52